Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.

Ditse Z, Muenchhoff M, Adland E, Jooste P, Goulder P, Moore PL, Morris L.

J Virol. 2018 Aug 16;92(17). pii: e00878-18. doi: 10.1128/JVI.00878-18. Print 2018 Sep 1.

2.

Correction for Anthony et al., "Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope".

Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Abdool Karim SS, Morris L, Wood NT, Moore PL, Williamson C.

J Virol. 2018 Apr 13;92(9). pii: e00243-18. doi: 10.1128/JVI.00243-18. Print 2018 May 1. No abstract available.

3.

HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.

Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, Abdool Karim S, Moore PL, Ackerman ME, Alter G, Morris L.

PLoS Pathog. 2018 Apr 9;14(4):e1006987. doi: 10.1371/journal.ppat.1006987. eCollection 2018 Apr.

4.

Case report: mechanisms of HIV elite control in two African women.

Moosa Y, Tanko RF, Ramsuran V, Singh R, Madzivhandila M, Yende-Zuma N, Abrahams MR, Selhorst P, Gounder K, Moore PL, Williamson C, Abdool Karim SS, Garrett NJ, Burgers WA.

BMC Infect Dis. 2018 Jan 25;18(1):54. doi: 10.1186/s12879-018-2961-8.

5.

Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.

Reh L, Magnus C, Kadelka C, Kühnert D, Uhr T, Weber J, Morris L, Moore PL, Trkola A.

PLoS Pathog. 2018 Jan 25;14(1):e1006825. doi: 10.1371/journal.ppat.1006825. eCollection 2018 Jan.

6.

The Neutralizing Antibody Response to the HIV-1 Env Protein.

Moore PL.

Curr HIV Res. 2018;16(1):21-28. doi: 10.2174/1570162X15666171124122044.

PMID:
29173180
7.

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Karim SA, Karim QA, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C.

PLoS Pathog. 2017 Sep 25;13(9):e1006641. doi: 10.1371/journal.ppat.1006641. eCollection 2017 Sep.

8.

Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses.

Scheepers C, Chowdhury S, Wright WS, Campbell CT, Garrett NJ, Abdool Karim Q, Abdool Karim SS, Moore PL, Gildersleeve JC, Morris L.

AIDS. 2017 Oct 23;31(16):2199-2209. doi: 10.1097/QAD.0000000000001643.

PMID:
28926408
9.

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.

Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH.

Sci Transl Med. 2017 Sep 6;9(406). pii: eaal1321. doi: 10.1126/scitranslmed.aal1321.

10.

A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies.

Mabvakure B, Scheepers C, Nonyane M, Lambson B, Madzorera S, Kitchin D, Bhiman J, Wibmer K, Abdool Karim S, Williamson C, Morris L, Moore PL.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.037. doi: 10.1093/ve/vew036.037. eCollection 2017 Mar. No abstract available.

11.

Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.

Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C.

J Virol. 2017 Aug 24;91(18). pii: e00828-17. doi: 10.1128/JVI.00828-17. Print 2017 Sep 15. Erratum in: J Virol. 2018 Apr 13;92 (9):.

12.

Size Doesn't Matter: Shorter Antibody Loops Can Infiltrate HIV's Env Apex Defenses.

Bhiman JN, Moore PL.

Immunity. 2017 May 16;46(5):762-764. doi: 10.1016/j.immuni.2017.04.012.

13.

Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.

Moore PL, Gorman J, Doria-Rose NA, Morris L.

Immunol Rev. 2017 Jan;275(1):217-229. doi: 10.1111/imr.12501. Review.

14.

Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.

Wibmer CK, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, Joyce MG, Ndabambi N, Druz A, Asokan M, Burton DR, Connors M, Abdool Karim SS, Mascola JR, Robinson JE, Ward AB, Williamson C, Kwong PD, Morris L, Moore PL.

PLoS Pathog. 2017 Jan 11;13(1):e1006074. doi: 10.1371/journal.ppat.1006074. eCollection 2017 Jan.

15.

Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies.

Moyo T, Ferreira RC, Davids R, Sonday Z, Moore PL, Travers SA, Wood NT, Dorfman JR.

Virology. 2017 Jan 15;501:12-24. doi: 10.1016/j.virol.2016.10.026. Epub 2016 Nov 13.

16.

HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.

Coss KP, Vasiljevic S, Pritchard LK, Krumm SA, Glaze M, Madzorera S, Moore PL, Crispin M, Doores KJ.

J Virol. 2016 Nov 28;90(24):11132-11144. Print 2016 Dec 15.

17.

Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens.

Shaffer JS, Moore PL, Kardar M, Chakraborty AK.

Proc Natl Acad Sci U S A. 2016 Oct 24. pii: 201614940. [Epub ahead of print]

18.

Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.

Wibmer CK, Gorman J, Anthony CS, Mkhize NN, Druz A, York T, Schmidt SD, Labuschagne P, Louder MK, Bailer RT, Abdool Karim SS, Mascola JR, Williamson C, Moore PL, Kwong PD, Morris L.

J Virol. 2016 Oct 28;90(22):10220-10235. Print 2016 Nov 15.

19.

Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection.

Muenchhoff M, Adland E, Karimanzira O, Crowther C, Pace M, Csala A, Leitman E, Moonsamy A, McGregor C, Hurst J, Groll A, Mori M, Sinmyee S, Thobakgale C, Tudor-Williams G, Prendergast AJ, Kloverpris H, Roider J, Leslie A, Shingadia D, Brits T, Daniels S, Frater J, Willberg CB, Walker BD, Ndung'u T, Jooste P, Moore PL, Morris L, Goulder P.

Sci Transl Med. 2016 Sep 28;8(358):358ra125. doi: 10.1126/scitranslmed.aag1048.

20.

Approaches to the induction of HIV broadly neutralizing antibodies.

Moore PL, Williamson C.

Curr Opin HIV AIDS. 2016 Nov;11(6):569-575. Review.

21.

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Abdool Karim S, Abdool Karim Q, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C.

PLoS Pathog. 2016 Jul 19;12(7):e1005742. doi: 10.1371/journal.ppat.1005742. eCollection 2016 Jul. Erratum in: PLoS Pathog. 2017 Sep 25;13(9):e1006641.

22.

Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women.

Mkhize NN, Durgiah R, Ashley V, Archary D, Garrett NJ, Karim QA, Karim SS, Moore PL, Yates N, Passmore JA, Tomaras GD, Morris L.

AIDS. 2016 Apr 24;30(7):1005-14. doi: 10.1097/QAD.0000000000001038.

23.

Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design.

Gorman J, Soto C, Yang MM, Davenport TM, Guttman M, Bailer RT, Chambers M, Chuang GY, DeKosky BJ, Doria-Rose NA, Druz A, Ernandes MJ, Georgiev IS, Jarosinski MC, Joyce MG, Lemmin TM, Leung S, Louder MK, McDaniel JR, Narpala S, Pancera M, Stuckey J, Wu X, Yang Y, Zhang B, Zhou T; NISC Comparative Sequencing Program, Mullikin JC, Baxa U, Georgiou G, McDermott AB, Bonsignori M, Haynes BF, Moore PL, Morris L, Lee KK, Shapiro L, Mascola JR, Kwong PD.

Nat Struct Mol Biol. 2016 Jan;23(1):81-90. doi: 10.1038/nsmb.3144. Epub 2015 Dec 21.

24.

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S, Pegu A, Schmidt SD, Staupe RP, Sutton MS, Wang K, Wibmer CK, Haynes BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR.

J Virol. 2015 Oct 14;90(1):76-91. doi: 10.1128/JVI.01791-15. Print 2016 Jan 1.

25.

Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.

Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, Abdool Karim SS, Shapiro L, Williamson C, Kwong PD, Mascola JR, Morris L, Moore PL.

Nat Med. 2015 Nov;21(11):1332-6. doi: 10.1038/nm.3963. Epub 2015 Oct 12.

26.

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.

Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, Williamson C, Moore PL, Morris L.

Retrovirology. 2015 Jun 24;12:54. doi: 10.1186/s12977-015-0183-3.

27.

Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.

Scheepers C, Shrestha RK, Lambson BE, Jackson KJ, Wright IA, Naicker D, Goosen M, Berrie L, Ismail A, Garrett N, Abdool Karim Q, Abdool Karim SS, Moore PL, Travers SA, Morris L.

J Immunol. 2015 May 1;194(9):4371-8. doi: 10.4049/jimmunol.1500118. Epub 2015 Mar 30.

28.

HIV broadly neutralizing antibody targets.

Wibmer CK, Moore PL, Morris L.

Curr Opin HIV AIDS. 2015 May;10(3):135-43. doi: 10.1097/COH.0000000000000153. Review.

29.

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Moore PL, Williamson C, Morris L.

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5. Review.

30.

Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.

Bandawe GP, Moore PL, Werner L, Gray ES, Sheward DJ, Madiga M, Nofemela A, Thebus R, Marais JC, Maboko L, Abdool Karim SS, Hoelscher M, Morris L, Williamson C.

J Infect Dis. 2015 May 1;211(9):1461-6. doi: 10.1093/infdis/jiu633. Epub 2014 Nov 14.

31.

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.

Derdeyn CA, Moore PL, Morris L.

Curr Opin HIV AIDS. 2014 May;9(3):210-6. doi: 10.1097/COH.0000000000000057. Review.

32.

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z; NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR.

Nature. 2014 May 1;509(7498):55-62. doi: 10.1038/nature13036. Epub 2014 Mar 2.

33.

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models.

Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, Karim SS, Mascola JR, Korber BT, Montefiori DC, Morris L, Williamson C, Seoighe C; CAVD-NSDP Consortium.

Virol J. 2013 Dec 2;10:347. doi: 10.1186/1743-422X-10-347.

34.

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL.

PLoS Pathog. 2013 Oct;9(10):e1003738. doi: 10.1371/journal.ppat.1003738. Epub 2013 Oct 31.

35.

Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

Alexandre KB, Moore PL, Nonyane M, Gray ES, Ranchobe N, Chakauya E, McMahon JB, O'Keefe BR, Chikwamba R, Morris L.

Virology. 2013 Nov;446(1-2):66-76. doi: 10.1016/j.virol.2013.07.019. Epub 2013 Aug 15.

36.

Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.

Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L.

J Virol. 2013 May;87(9):4882-94. doi: 10.1128/JVI.03424-12. Epub 2013 Feb 13.

37.

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L.

Nat Med. 2012 Nov;18(11):1688-92. doi: 10.1038/nm.2985. Epub 2012 Oct 21.

38.

UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Mufhandu HT, Gray ES, Madiga MC, Tumba N, Alexandre KB, Khoza T, Wibmer CK, Moore PL, Morris L, Khati M.

J Virol. 2012 May;86(9):4989-99. doi: 10.1128/JVI.06893-11. Epub 2012 Feb 29.

39.

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.

J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17.

40.

Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site.

Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L.

J Virol. 2011 Sep;85(17):9039-50. doi: 10.1128/JVI.02675-10. Epub 2011 Jun 22.

41.

Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.

Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, Moore PL, Foulger A, Yu JS, Lambson B, Abdool Karim S, Whitesides J, Tomaras GD, Haynes BF, Morris L, Liao HX.

J Virol. 2011 Aug;85(15):7719-29. doi: 10.1128/JVI.00563-11. Epub 2011 May 25.

42.

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L; CAPRISA002 Study Team.

J Virol. 2011 May;85(10):4828-40. doi: 10.1128/JVI.00198-11. Epub 2011 Mar 9.

43.

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; CAPRISA 002 Study.

J Virol. 2011 Apr;85(7):3128-41. doi: 10.1128/JVI.02658-10. Epub 2011 Jan 26.

44.

Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin.

Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L.

Virology. 2010 Jun 20;402(1):187-96. doi: 10.1016/j.virol.2010.03.021. Epub 2010 Apr 13.

45.

Specificity of the autologous neutralizing antibody response.

Moore PL, Gray ES, Morris L.

Curr Opin HIV AIDS. 2009 Sep;4(5):358-63. doi: 10.1097/COH.0b013e32832ea7e8. Review.

46.

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L; CAPRISA 002 Study; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.

47.

Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates.

Singh A, Page T, Moore PL, Allgaier RL, Hiramen K, Coovadia HM, Walker BD, Morris L, Ndung'u T.

Virology. 2009 Oct 10;393(1):56-67. doi: 10.1016/j.virol.2009.07.021. Epub 2009 Aug 19.

48.

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L.

J Virol. 2009 Nov;83(21):11265-74. doi: 10.1128/JVI.01359-09. Epub 2009 Aug 19.

49.

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.

J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.

50.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

Supplemental Content

Loading ...
Support Center